Publication Name	World Journal of Clinical Cases
Manuscript ID	13073
Country

Received	2014-08-04 18:24
Peer-Review Started	2014-08-06 15:03
To Make the First Decision	2014-09-16 10:58
Return for Revision	2014-09-18 15:41
Revised	2014-10-09 10:43
Second Decision	2014-11-12 14:12
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-11-19 10:46
Articles in Press	2014-11-19 10:47
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-01-05 16:40
Publish the Manuscript Online	2015-01-14 10:56

ISSN	2307-8960 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Recent advances in the HER2 targeted therapy of gastric cancer
Manuscript Source	Invited Manuscript
All Author List	Tasuku Matsuoka and Masakazu Yashiro
Funding Agency and Grant Number
Corresponding Author	Masakazu Yashiro, MD, Oncology Institute of Geriatrics and Medical Science, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan. m9312510@med.osaka-cu.ac.jp
Key Words	Human epidermal growth factor receptor 2; Gastric cancer; Targeting therapy; Trastuzumab
Core Tip	This review summarizes the development of diagnostic and therapeutic approach for the patients with human epidermal growth factor receptor 2 (HER2)-overexpressed/amplified gastric cancer. The biology of HER2-dependent signalling is also described. The ToGA trial highlighted the importance of accurate HER2 testing to guide treatment choice of gastric cancer. Future strategies beyond the ToGA trial to address EFGR family, including HER2 pathway are discussed according to current ongoing clinical trials, as well as experimental studies.
Publish Date	2015-01-14 10:56
Citation	Matsuoka T, Yashiro M. Recent advances in the HER2 targeted therapy of gastric cancer. World J Clin Cases 2015; 3(1): 42-51
URL	http://www.wjgnet.com/2307-8960/full/v3/i1/42.htm
DOI	http://dx.doi.org/10.12998/wjcc.v3.i1.42

Full Article (PDF)	WJCC-3-42.pdf
Full Article (Word)	WJCC-3-42.doc
Manuscript File	13073-Review.docx
Answering Reviewers	13073-Answering reviewers.pdf
Copyright License Agreement	13073-Copyright assignment.pdf
Peer-review Report	13073-Peer review(s).pdf
Scientific Misconduct Check	13073-CrossCheck.jpg
Scientific Editor Work List	13073-Scientific editor work list.pdf